Regulatory round-up: 5 January 2026

The holiday period typically thins out formal decisions, but several regulators still published material updates spanning approvals, policy consultations, and authorization summaries.

The UK regulator was the most active, starting 2026 with a COVID-19 vaccine decision, while Canada and Brazil focused on regulatory frameworks rather than product-specific rulings.

Swissmedic, meanwhile, continued to release public assessment documentation linked to recent authorization activity, maintaining transparency during a quieter reporting window.